{"protocolSection":{"identificationModule":{"nctId":"NCT05395351","orgStudyIdInfo":{"id":"0135-0348"},"organization":{"fullName":"Boehringer Ingelheim","class":"INDUSTRY"},"briefTitle":"Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization","officialTitle":"Characteristics and In-hospital Outcomes of Chinese Elderly (>80 Years) Patients With Acute Ischemic Stroke Receiving Intravenous Recombinant Tissue Plasminogen Activator Treatment Within 4.5 Hours of Symptom Onset"},"statusModule":{"statusVerifiedDate":"2023-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-11-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-03-28","type":"ACTUAL"},"completionDateStruct":{"date":"2023-03-28","type":"ACTUAL"},"studyFirstSubmitDate":"2022-05-25","studyFirstSubmitQcDate":"2022-05-25","studyFirstPostDateStruct":{"date":"2022-05-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-04-14","lastUpdatePostDateStruct":{"date":"2023-04-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Boehringer Ingelheim","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom onset in different age groups (18 to 80 years and above 80 years)."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"RETROSPECTIVE"},"enrollmentInfo":{"count":113035,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1: IV rt-PA cohort with AIS patients aged >80 years","description":"AIS patients aged \\>80 years who received IV rt-PA within 4.5 hours of symptom onset.","interventionNames":["Drug: rt-PA"]},{"label":"Group 2: IV rt-PA cohort with AIS patients aged 18 to 80 years","description":"AIS patients aged 18 to 80 years who received IV rt-PA within 4.5 hours of symptom onset.","interventionNames":["Drug: rt-PA"]},{"label":"Group 3: Non-reperfusion cohort with AIS patients aged >80 years","description":"AIS patients aged \\>80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive thrombolysis treatment."},{"label":"Group 4: Non-reperfusion cohort with AIS patients aged 18 to 80 years","description":"AIS patients aged 18 to 80 years who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive thrombolysis treatment."}],"interventions":[{"type":"DRUG","name":"rt-PA","description":"Recombinant Tissue Plasminogen Activator","armGroupLabels":["Group 1: IV rt-PA cohort with AIS patients aged >80 years","Group 2: IV rt-PA cohort with AIS patients aged 18 to 80 years"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"All-cause mortality during hospitalization","description":"analyzed for patients in Group 1 and Group 2","timeFrame":"up to 3 months"}],"secondaryOutcomes":[{"measure":"Proportion of patients with hemorrhagic stroke during hospitalization","description":"analyzed for patients in Group 1 and Group 2","timeFrame":"up to 3 months"},{"measure":"Change of National Institutes of Health Stroke Scale (NIHSS) score from before IV rt-PA treatment to 24 hours after IV rt-PA treatment","description":"analyzed for patients in Group 1 and Group 2 The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss.\n\nNIHSS scores range from 0 - 42. A score of 0 indicates no stroke symptoms. Higher scores indicate incremental levels of neurological impairment.","timeFrame":"baseline and 24 after IV rt-PA treatment"},{"measure":"modified Rankin Scale (mRS) score at discharge","description":"analyzed for patients in Group 1 and Group 2 The modified Rankin Scale (mRS) is used for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, from 'perfect health without symptoms' to 'death'. 0 - No symptoms.\n\n1. - No significant disability. Able to carry out all usual activities, despite some symptoms.\n2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.\n3. - Moderate disability. Requires some help, but able to walk unassisted.\n4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.\n5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.\n6. - Dead.","timeFrame":"up to 3 months"},{"measure":"Proportion of patients with stroke recurrence during hospitalization","description":"analyzed for patients in Group 1 and Group 2","timeFrame":"up to 3 months"},{"measure":"Length of hospitalization","description":"analyzed for patients in Group 1 and Group 2","timeFrame":"up to 3 months"},{"measure":"Percentage of IV rt-PA treatment among AIS patients arrived or were admitted to the hospital within 4.5 hours of symptom onset","description":"The percentage of IV rt-PA treatment will be calculated based on age groups (18-80 years and \\>80 years).","timeFrame":"up to 3 months"},{"measure":"Percentage of IV rt-PA treatment within 4.5 hours of symptom onset among eligible AIS patients (3.5-hour arrival or admission)","description":"The percentage of IV rt-PA treatment will be calculated based on age groups (18-80 years and \\>80 years).","timeFrame":"up to 3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient registered in the Chinese Stroke Centre Alliance (CSCA) platform from Aug 2015 to Jul 2019\n* ≥18 years old\n* Diagnosed as Acute Ischemic Stroke (AIS) at admission\n* Arrived or admitted into hospital within 4.5 hours of symptom onset\n* For patients in the iv rt-PA groups only: received IV rt-PA within 4.5 hours of symptom onset\n\nExclusion Criteria:\n\n* Documented Intravenous Thrombolysis (IVT) absolute contraindication\n* Key data missing (age, gender, baseline National Institutes of Health Stroke Scale \\[NIHSS\\], time of symptom onset, IVT treated or not, time of IV alteplase treatment)\n* Received thrombolysis agents other than IV rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)\n* Received endovascular treatment\n* Received IV rt-PA after 4.5 hours of symptom onset","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Acute ischemic stroke (AIS) patients who were treated with Intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) or did not receive thrombolysis treatment within 4.5 hours of symptom onset, aged ≥18 years old.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Boehringer Ingelheim (China) Investment Co., ltd.","city":"Shanghai","zip":"200040","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Related Info","url":"https://www.mystudywindow.com"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).\n\nFor more details refer to: https://www.mystudywindow.com/msw/datatransparency"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}